EX-10.28 2 ttoo-20161231ex10282c167.htm EX-10.28 Confidential CO-DEVELOPMENT, COLLABORATION AND CO-MARKETING AGREEMENTCo-Development, Collaboration and Co-Marketing Agreement • May 5th, 2020 • New York
This Co-Development, Collaboration and Co-Marketing Agreement (the “Agreement”) is entered into on November 1, 2016 (the “Effective Date”) by and between T2 Biosystems, Inc., a Delaware corporation (“T2 Bio”), having its principal offices at 101 Hartwell Avenue, Lexington, Massachusetts 02421, and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”), having its principal offices at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054. T2 Bio and Allergan are each a “Party” and together the “Parties” to this Agreement.
AMENDMENT TO CO-DEVELOPMENT, COLLABORATION AND CO-MARKETING AGREEMENTCo-Development, Collaboration and Co-Marketing Agreement • August 4th, 2017 • T2 Biosystems, Inc. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO CO-DEVELOPMENT, COLLABORATION AND CO-MARKETING AGREEMENT (this “Amendment”) is entered into on June 1, 2017 (the “Amendment Effective Date”), by and between T2 Biosystems, Inc., a Delaware corporation (“T2 Bio”), and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”). Capitalized terms used herein without definition shall have the meaning ascribed thereto in the Agreement (as defined below).
